What should a CJC-1295 price Australia quote include besides the listed figure?
A quoted CJC-1295 price Australia figure is only a starting point for laboratory procurement. The analogue is a relatively long synthetic peptide, and lots that carry a drug-affinity-complex (DAC) maleimide modification require additional synthetic, purification and identity-confirmation steps compared with an unmodified GRF(1-29) sequence. Preparative HPLC, orthogonal mass spectrometry and CoA compilation all sit inside the unit price whether or not they are itemised.
Laboratories should unbundle every quote into listed fill mass, the analytical package that accompanies that fill, and fulfilment terms that can be verified in Australia. Listed fill mass without net peptide content is a gross mass of lyophilised cake that may include counterion, residual water and related substances. Two vendors can print the same milligram number on a vial and still supply different amounts of the target polypeptide. The lower line item is not lower cost if the CoA shows weaker identity data or a smaller peptide fraction.
Identity by electrospray ionisation mass spectrometry, reversed-phase HPLC purity with a related-substances table, and a batch identifier linking the vial to chromatograms and spectra are the minimum that makes a research material usable in a documented method. Lots offered without those artefacts cannot be ranked on price, because the buyer cannot tell whether the material is the intended analogue. Identification of CJC-1295 in an unknown pharmaceutical preparation showed that a label is not evidence of chemical identity (PMID:21204297).
Fulfilment terms that belong in an Australian comparison include local stock, so the lot on the CoA is the lot that ships, tracked dispatch, and a documentation pack issued per batch rather than a generic brochure. ClaraScience frames research-peptide supply around those attributes. The correct question is which listing states, in SI units and named methods, what the laboratory is paying for.
How is CJC-1295 chemically defined before a quoted milligram is meaningful?
Before a milligram price is meaningful, the laboratory must state which molecular entity is being purchased. CJC-1295 is identified in the endocrine chemistry literature as an hGRF(1-29) analogue constructed so that a reactive moiety can form an albumin bioconjugate. Jetté and co-workers described human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates and identified CJC-1295 as a GRF analogue in that series (PMID:15817669). For procurement, that description becomes a set of identity checks: the amino-acid sequence of the GRF(1-29) core, the presence or absence of the DAC maleimide handle, the expected monoisotopic and average masses of the intact species, and the absence of a dominant unconjugated or truncated species in the HPLC-MS record.
Those checks are not optional. Henninge and co-workers identified CJC-1295 in an unknown pharmaceutical preparation, showing that materials circulating under that name require independent chemical identification rather than reliance on the printed label (PMID:21204297). A research buyer comparing Australian quotes should treat the storefront name as a hypothesis. If one CoA reports an intact mass consistent with the DAC-modified sequence and another reports only a nominal HPLC area-percent with no mass, the line items are different goods and price-per-milligram arithmetic between them is undefined.
The CoA should state the theoretical mass, the observed m/z envelope under electrospray ionisation, the deconvoluted intact mass, and the mass error in daltons or parts per million. Sequence-informative fragment ions, where recorded, reduce the risk that a co-eluting isomer or a closely related GHRH analogue has been substituted. Detection literature for synthetic GHRH analogues emphasises that several related structures can occupy the same analytical window, so a single nominal mass without chromatographic context is a weak identifier (PMID:34665524). DAC-bearing lots and unmodified GRF(1-29) lots have different molecular weights, impurity profiles and synthetic routes; mixing them in a price spreadsheet is a category error. If the identity section does not lock the structure to a stated sequence and modification, the quote should not enter the numerical comparison.
Which HPLC purity fields on a CoA actually change cost per milligram?
Reversed-phase HPLC is the routine purity method for synthetic GHRH analogues. For procurement, the chromatogram is evidence that listed milligrams are predominantly one peak. Laboratories should require column chemistry (typically C18), organic modifier and ion-pair reagent, detection wavelength, integration events, and a related-substances table listing each peak above a stated reporting threshold as area-percent.
Area-percent HPLC purity is not peak purity. Diode-array ratiograms or purity-angle criteria ask whether the main peak is spectrally homogeneous. A high area-percent with a failing peak-purity index suggests co-elution, which overstates the quoted purity and understates the true cost of the intended analogue. Orthogonal mass detection on the same or a paired method resolves that ambiguity: extracted-ion traces show whether the main ultraviolet peak is a single intact mass or a composite.
Acceptance criteria belong in the specification. A research lot should be released against a documented HPLC purity minimum and a cap on unidentified related substances. Those numbers are method-specific. Changing the ion-pair reagent, for example trifluoroacetic acid versus formic acid, can alter selectivity and apparent purity. Quotes that do not name the method are not comparable. System suitability should be visible in the batch file: retention-time windows, tailing, resolution to a critical impurity where known, and injection-sequence controls such as blanks and bracketing injections. A single chromatogram without those controls does not demonstrate that the method was in control when the lot was tested. The cost of generating that file is part of a research-grade price. Listings that claim high purity without chromatograms should be treated as having unestablished purity and should not benchmark an Australian unit price. Purity is a measured quantity, not a slogan.
How do net peptide content and counterion normalise listed vial mass?
Listed vial mass is a gross figure. Net peptide content is the fraction of that mass that is polypeptide rather than counterion, residual moisture and other non-peptide mass. Laboratories that compare CJC-1295 on a dollars-per-listed-milligram basis mis-rank vendors whenever net content differs.
Counterion is the first correction. Preparative reversed-phase purification commonly leaves trifluoroacetate unless a salt exchange to acetate or another anion has been performed and documented. Trifluoroacetate and acetate contribute different non-peptide masses. A CoA that omits the counterion, or that states a TFA salt without a measured percentage, leaves the buyer unable to convert listed milligrams into milligrams of peptide. Quantitative counterion methods belong in the lot file when price is being normalised.
Water is the second correction. Karl Fischer titration is the standard approach for residual moisture on lyophilised peptides. Combined with counterion, it explains why two lots with the same printed fill can differ widely in net peptide content. A transparent quote therefore presents listed fill in milligrams, water as a percentage, counterion identity and percentage, HPLC purity as area-percent of the intended peak, and net peptide content as a percentage. The like-for-like comparator is price divided by listed fill times net peptide content times the HPLC purity fraction, not price divided by listed fill. Skipping this normalisation prefers the vendor who prints the largest milligram number rather than the vendor who supplies the largest quantity of the intended analogue.
Net content also interacts with identity. If mass spectrometry shows that a substantial related substance shares the ultraviolet response of the main peak, HPLC area-percent overstates the intended sequence. Net-content arithmetic is therefore the second filter, after identity, not a substitute for it. ClaraScience documentation is organised so these fields can be read together on a single lot, which is the only basis on which an Australian unit price can be interpreted.
Which MS results and Australian lot documents should sit behind the unit price?
Beyond intact-mass confirmation, analytical literature describes targeted detection of GHRH synthetic analogues, including CJC-1295. Memdouh and co-workers reviewed chromatographic and mass-spectrometric strategies used to distinguish related structures (PMID:34665524). The procurement takeaway is that several closely related analogues can appear under similar names and that methods with adequate selectivity are required before a vial label is accepted.
Confirmatory LC-MS/MS methods have been published for CJC-1295 in plasma matrices, using targeted transitions after sample preparation (PMID:30938069). Immunoaffinity enrichment prior to liquid chromatography-mass spectrometry is a documented strategy for peptide hormones in complex samples (PMID:21871962). An immuno-polymerase chain reaction screen has been described for CJC-1295 and other GHRH analogues in equine plasma (PMID:30489688). Those papers are matrix-specific and were written for detection programmes. They are cited only to show that high-selectivity identity tools exist, and that a research CoA which stops at a single ultraviolet peak sits well below the selectivity already applied to this analogue class. A proportionate lot file should include intact mass with stated error, preferably fragment-ion support for the GRF core and the DAC modification, and HPLC related-substances data that would reveal a substituted analogue. If a vendor claims a confirmatory method, the method name, instrument type and acceptance window should be written down. A sentence that merely says MS confirmed is not a result.
Once identity and purity are specified, remaining price variance is largely documentation and fulfilment. A research-grade Australian quote should name the same batch or lot number on the invoice, the CoA and the vial label, and should provide a batch report that can be archived with the laboratory protocol. Local Australian stock ties the CoA to the physical vials that will be dispatched. A catalogue chromatogram from an unrelated campaign is not lot documentation. Tracked dispatch provides a chain-of-custody artefact from warehouse to receiving bench. ClaraScience uses local stock, tracked dispatch and batch documentation issued with the material. The quote and the label must state research use only. The close of an Australian price comparison is a table of normalised cost per milligram of documented analogue plus a checklist: sequence and modification locked by MS, HPLC method named, net content and counterion reported, lot numbers aligned, local stock confirmed, dispatch tracked. Listings that fail the checklist are incomplete materials, not bargains.
Order Cjc 1295 with documentation
If this guide helped you evaluate Cjc 1295 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Cjc 1295 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Why do two Australian CJC-1295 quotes differ if both list the same milligram fill?
Listed fill is gross lyophilised mass. Counterion, residual water, HPLC related substances and whether mass spectrometry has locked the DAC-modified GRF(1-29) sequence all change how much intended analogue is in the vial. Normalise price by net peptide content and documented purity before ranking vendors. Materials are research use only.
Is HPLC area-percent enough to compare CJC-1295 on a per-milligram basis?
No. Area-percent does not prove spectral homogeneity of the main peak and does not identify the analogue. Peak-purity indices and orthogonal intact-mass data are needed so co-eluting related substances are not priced as if they were the target sequence. HPLC method conditions must be named on the CoA for any comparison to be valid.
What mass-spectrometry result should match the intended research analogue?
The CoA should report theoretical mass, observed charge states, deconvoluted intact mass and mass error. Where available, fragment ions should support the GRF(1-29) core and the DAC modification. A label without those values is not an identity result. Published work has identified CJC-1295 in unknown pharmaceutical preparations, so the printed name alone is insufficient.
How does counterion affect a like-for-like Australian price comparison?
Trifluoroacetate and acetate contribute different non-peptide mass to the lyophilised cake. Without a stated counterion and a measured percentage, listed milligrams cannot be converted into milligrams of polypeptide. Include counterion and Karl Fischer water with net peptide content when comparing quotes. These materials are research reagents only.
Does local Australian stock change the procurement comparison?
Yes. Local stock links the CoA lot number to the vials that are dispatched. Tracked dispatch adds a chain-of-custody record from warehouse to receiving bench. A chromatogram that is not lot-specific is not documentation. Those fulfilment attributes are part of what a research laboratory is paying for, alongside HPLC and MS data.
What must appear on a research-only CoA besides a purity percentage?
Batch or lot number aligned to the vial, named HPLC method, related-substances table, intact-mass result with error, counterion identity, water or net peptide content, and a research-use-only statement. Missing fields mean the unit price cannot be interpreted as cost per milligram of the intended analogue.
References
- PMID:15817669 — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Endocrinology — 2005
- PMID:21204297 — Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation — Drug Test Anal — 2010
- PMID:34665524 — Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal — 2021
- PMID:30938069 — A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug Test Anal — 2019
- PMID:21871962 — Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls — Methods — 2012
- PMID:30489688 — An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug Test Anal — 2019
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
